Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-04-22
2008-04-22
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S414000, C514S217040, C514S228200, C514S235200, C514S316000, C514S323000, C540S597000, C544S124000, C544S144000, C546S187000, C546S201000, C548S468000
Reexamination Certificate
active
07361682
ABSTRACT:
The present invention relates to compounds of formula I:wherein X, R1, R2, R3, R4and R5are as defined in the description and claims, and pharmaceutically acceptable salts thereof, to the preparation of such compounds and pharmaceutical compositions containing them. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
REFERENCES:
patent: 6673829 (2004-01-01), Dorwald et al.
patent: 6919355 (2005-07-01), Horvath et al.
patent: 0 624 575 (1994-11-01), None
patent: 0 978 512 (2000-02-01), None
patent: WO 01/74773 (2001-10-01), None
patent: WO 02/072548 (2002-09-01), None
patent: WO 04/000831 (2003-12-01), None
Witkin et al. Pharmacology & Therapeutics 2004, 103, 1-20.
Burks 1994 in Johnson L.R. ed., Physiology of the Gastrointestinal Tract, Raven Press, NY, pp. 211-242.
Leurs et al., Br J. Pharmacol. 1991, 102, pp. 179-185.
Raithel et al., Int. Arch. Allergy Immunol. 1995, 108, 127-133.
Panula et al., Proc. Natl. Acad. Sci. USA 1984, 81, 2572-2576.
Inagaki et al., J. Comp. Neurol 1988, 273, 283-300.
Arrang et al., Nature 1983, 302, 832-837.
Arrang et al., Neuroscience 1987, 23, 149-157.
Clapham & Kilpatrik, Br. J. Pharmacol. 1982, 107, 919-923.
Blandina et al. in The Histamine H3 Receptor (Leurs RL and Timmermann H eds, 1998, pp. 27-40.
Masaki et al; Endocrinol. 2003, 144, 2741-2748.
Hancock et al., European J. of Pharmacol. 2004, 487, 183-197.
Timmermann, J. Med. Chem. 1990, 33, 4-11.
Brashear, K.M., et al., Bioorganic and Medicinal Chemistry Letters, vol. 7, No. 21, pp. 2793-2798 (1997), XP002347978.
Gatti McArthur Silvia
Hertel Cornelia
Nettekoven Matthias Heinrich
Plancher Jean-Marc
Raab Susanne
Hoffmann-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Nolan Jason M
Saeed Kamal A.
LandOfFree
Indole derivatives as H3 inverse agonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indole derivatives as H3 inverse agonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indole derivatives as H3 inverse agonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2757805